Moderna
Merck
said it is exercising an option to research a personalized cancer vaccine with the Covid-19 vaccine maker.
Moderna
(MRNA) $250 million for joint development and future commercialization of the vaccine, currently in phase 2 clinical trials. The two companies announced a “strategic cooperation“In June 2016.
